首页 > 最新文献

Catheterization and Cardiovascular Interventions最新文献

英文 中文
Impact of a dedicated radial lounge on same-day discharge percutaneous coronary intervention 专用桡动脉休息室对当天出院经皮冠状动脉介入治疗的影响。
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-16 DOI: 10.1002/ccd.31208
Federico Liberman MD, Fernando Botto MD, MSc, Mariano N. Benzadon MD, Pablo M. Lamelas MD, MSc, Pablo M. Spaletra MD, Pablo D. Mascolo MD, Santiago Ordoñez MD, Lucio T. Padilla MD, Gustavo O. Pedernera MD, Jorge Belardi MD, Fernando A. Cura MD, PhD

Background

The same-day discharge (SDD) program after elective percutaneous coronary intervention (PCI) is a safe strategy that allows for the optimization of hospital resources. However, the lack of adequate infrastructure and a specially targeted care model may limit its implementation. Our center developed an outpatient care model based on an area designed for percutaneous procedures called radial lounge (RL).

Aims

Evaluate the efficacy and safety of the RL care model: (1) SDD rate, (2) patient experience, (3) major adverse cardiac events (MACEs) (in-hospital, 30-day, and 1-year mortality and intervention), and (4) vascular access complication. Secondary objective: Impact of RL SDD rate on total elective SDD-PCI volume.

Methods

We conducted a retrospective observational cohort study at a cardiovascular hospital, including consecutive patients undergoing elective PCI between 2015 and 2022 who were admitted to the conventional hospitalization area (CHA) or the RL about the stated objectives. Patient experience was assessed using the Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey.

Results

A total of 5466 elective PCI procedures were included: 2102 in the RL and 3364 in the CHA. The SDD rate was 85.2% in the RL group and 54% in the CHA. After the implementation of RL, a significant increase in the volume of elective SDD-PCI was observed and patient satisfaction improved significantly (p < 0.005) with CHA. Finally, a greater amount of MACEs were not observed in the RL.

Conclusions

The PCI program in RL proved to be safe and effective. It showed a higher rate of SDD and a significant improvement in patient experience was observed without affecting safety.

背景:择期经皮冠状动脉介入治疗(PCI)后的当日出院(SDD)计划是一种安全的策略,可以优化医院资源。然而,缺乏足够的基础设施和有针对性的护理模式可能会限制其实施。目的:评估 RL 护理模式的有效性和安全性:(1) SDD 率;(2) 患者体验;(3) 主要心脏不良事件 (MACE)(院内、30 天和 1 年死亡率及介入治疗);(4) 血管通路并发症: 次要目标:RL SDD 率对择期 SDD-PCI 总量的影响:我们在一家心血管医院开展了一项回顾性观察队列研究,研究对象包括 2015 年至 2022 年期间接受择期 PCI 的连续患者,这些患者均在常规住院区(CHA)或 RL 就既定目标住院。患者体验通过医疗服务提供者和系统消费者评估(HCAHPS)调查进行评估:结果:共纳入 5466 例择期 PCI 手术:结果:共纳入 5466 例择期 PCI 手术:2102 例纳入 RL,3364 例纳入 CHA。RL组的SDD率为85.2%,CHA组为54%。在实施 RL 后,观察到择期 SDD-PCI 的数量显著增加,患者的满意度也明显提高(p 结论:RL 的 PCI 计划被证明是一种有效的治疗方法:事实证明,RL 的 PCI 项目安全有效。在不影响安全性的前提下,它提高了 SDD 率,并明显改善了患者的就医体验。
{"title":"Impact of a dedicated radial lounge on same-day discharge percutaneous coronary intervention","authors":"Federico Liberman MD,&nbsp;Fernando Botto MD, MSc,&nbsp;Mariano N. Benzadon MD,&nbsp;Pablo M. Lamelas MD, MSc,&nbsp;Pablo M. Spaletra MD,&nbsp;Pablo D. Mascolo MD,&nbsp;Santiago Ordoñez MD,&nbsp;Lucio T. Padilla MD,&nbsp;Gustavo O. Pedernera MD,&nbsp;Jorge Belardi MD,&nbsp;Fernando A. Cura MD, PhD","doi":"10.1002/ccd.31208","DOIUrl":"10.1002/ccd.31208","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The same-day discharge (SDD) program after elective percutaneous coronary intervention (PCI) is a safe strategy that allows for the optimization of hospital resources. However, the lack of adequate infrastructure and a specially targeted care model may limit its implementation. Our center developed an outpatient care model based on an area designed for percutaneous procedures called radial lounge (RL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Evaluate the efficacy and safety of the RL care model: (1) SDD rate, (2) patient experience, (3) major adverse cardiac events (MACEs) (in-hospital, 30-day, and 1-year mortality and intervention), and (4) vascular access complication. Secondary objective: Impact of RL SDD rate on total elective SDD-PCI volume.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective observational cohort study at a cardiovascular hospital, including consecutive patients undergoing elective PCI between 2015 and 2022 who were admitted to the conventional hospitalization area (CHA) or the RL about the stated objectives. Patient experience was assessed using the Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 5466 elective PCI procedures were included: 2102 in the RL and 3364 in the CHA. The SDD rate was 85.2% in the RL group and 54% in the CHA. After the implementation of RL, a significant increase in the volume of elective SDD-PCI was observed and patient satisfaction improved significantly (<i>p</i> &lt; 0.005) with CHA. Finally, a greater amount of MACEs were not observed in the RL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The PCI program in RL proved to be safe and effective. It showed a higher rate of SDD and a significant improvement in patient experience was observed without affecting safety.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":"104 6","pages":"1189-1195"},"PeriodicalIF":2.1,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined antegrade and retrograde dissection and re-entry techniques: A two-in-one chronic total occlusion procedure 结合前行和逆行剥离和再进入技术:二合一慢性全闭塞手术。
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-16 DOI: 10.1002/ccd.31265
Randal Jun Bang Low MBBS, MRCP, Maciej Marciniak MD, PhD, Thomas Kaier MD, MBA, PhD, Antonis Pavlidis MD, PhD

Treatment of chronic total occlusions (CTOs) by percutaneous coronary intervention (PCI) is technically challenging, with exponential difficulty in the presence of specific anatomical features. We present a complex case where procedural success was achieved by sequential PCIs to two separate CTOs in a ‘two-in-one’ procedure.

通过经皮冠状动脉介入治疗(PCI)治疗慢性全闭塞(CTO)在技术上极具挑战性,如果存在特殊的解剖特征,难度会成倍增加。我们介绍了一个复杂病例,该病例在 "二合一 "手术中对两个不同的 CTO 顺序进行了 PCI 治疗,取得了手术成功。
{"title":"Combined antegrade and retrograde dissection and re-entry techniques: A two-in-one chronic total occlusion procedure","authors":"Randal Jun Bang Low MBBS, MRCP,&nbsp;Maciej Marciniak MD, PhD,&nbsp;Thomas Kaier MD, MBA, PhD,&nbsp;Antonis Pavlidis MD, PhD","doi":"10.1002/ccd.31265","DOIUrl":"10.1002/ccd.31265","url":null,"abstract":"<p>Treatment of chronic total occlusions (CTOs) by percutaneous coronary intervention (PCI) is technically challenging, with exponential difficulty in the presence of specific anatomical features. We present a complex case where procedural success was achieved by sequential PCIs to two separate CTOs in a ‘two-in-one’ procedure.</p>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":"104 6","pages":"1211-1216"},"PeriodicalIF":2.1,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of prior hospitalization for heart failure on clinical outcomes of patients after transcatheter aortic valve implantation with new-generation devices: Insights from the LAPLACE-TAVI registry. 经导管主动脉瓣新一代设备植入术后患者之前因心衰住院对临床预后的影响:LAPLACE-TAVI 登记的启示。
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-14 DOI: 10.1002/ccd.31261
Motoki Fukutomi, Takayuki Onishi, Tomo Ando, Ryosuke Higuchi, Kenichi Hagiya, Mike Saji, Itaru Takamisawa, Nobuo Iguchi, Morimasa Takayama, Atsushi Shimizu, Jun Shimizu, Shinichiro Doi, Shinya Okazaki, Kei Sato, Harutoshi Tamura, Hiroaki Yokoyama, Shuichiro Takanashi, Tetsuya Tobaru

Background: A history of hospitalization for heart failure (HHF) before transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement is associated with the prognosis of patients with severe aortic stenosis (AS). However, the impact of prior HHF on clinical outcomes after contemporary TAVI using new-generation transcatheter heart valves (THVs) has not been thoroughly investigated.

Methods: Using data from the aLliAnce for exPloring cLinical prospects of AortiC valvE disease (LAPLACE)-TAVI registry, we investigated 2,752 patients who underwent TAVI with new-generation THVs with a median follow-up of 627 days. The primary outcomes were all-cause mortality and heart failure readmission after TAVI.

Results: Patients with a history of HHF (n = 809) showed a higher 30-day mortality than patients without prior HHF (n = 1,943). A Kaplan-Meier analysis revealed that the prior HHF group showed a higher incidence of the primary outcome than the non-prior HHF group (27.4% vs. 16.4%, log-rank p = 0.001). In a Cox regression analysis, prior HHF was significantly associated with the risk of the primary outcome, even after adjusting for covariates (hazard ratio, 1.344; 95% confidence interval, 1.103-1.638; p = 0.003). A subanalysis showed that the prior HHF group with ejection fraction (EF) ≥ 50% had a higher risk of the primary outcome than the non-prior HHF group, whereas the prior HHF group with EF < 50% had the worst outcome.

Conclusion: A history of prior HHF is associated with worse outcomes in patients with severe AS, both in those with preserved EF and those with reduced EF, even after TAVI using new-generation devices.

背景:经导管主动脉瓣植入术(TAVI)或手术主动脉瓣置换术前的心力衰竭(HHF)住院史与重度主动脉瓣狭窄(AS)患者的预后有关。然而,对于使用新一代经导管心脏瓣膜(TAVI)进行当代TAVI术后,既往HHF对临床预后的影响尚未进行深入研究:方法: 我们利用新一代经导管心脏瓣膜(THV)临床前景评估(LAPLACE)-TAVI 登记数据,对 2752 名接受 TAVI 的患者进行了调查,中位随访时间为 627 天。主要结果是全因死亡率和TAVI术后心衰再入院率:结果:有HHF病史的患者(809人)的30天死亡率高于无HHF病史的患者(1943人)。Kaplan-Meier分析显示,既往有HHF病史组的主要结局发生率高于无HHF病史组(27.4%对16.4%,log-rank p = 0.001)。在 Cox 回归分析中,即使调整了协变量,既往 HHF 仍与主要结局的风险显著相关(危险比为 1.344;95% 置信区间为 1.103-1.638;P = 0.003)。一项子分析表明,射血分数(EF)≥50%的既往HHF组发生主要结局的风险高于非既往HHF组,而射血分数(EF)≥50%的既往HHF组发生主要结局的风险高于非既往HHF组:既往HHF史与重度AS患者较差的预后有关,无论是EF保留的患者还是EF降低的患者,即使在使用新一代设备进行TAVI后也是如此。
{"title":"Impact of prior hospitalization for heart failure on clinical outcomes of patients after transcatheter aortic valve implantation with new-generation devices: Insights from the LAPLACE-TAVI registry.","authors":"Motoki Fukutomi, Takayuki Onishi, Tomo Ando, Ryosuke Higuchi, Kenichi Hagiya, Mike Saji, Itaru Takamisawa, Nobuo Iguchi, Morimasa Takayama, Atsushi Shimizu, Jun Shimizu, Shinichiro Doi, Shinya Okazaki, Kei Sato, Harutoshi Tamura, Hiroaki Yokoyama, Shuichiro Takanashi, Tetsuya Tobaru","doi":"10.1002/ccd.31261","DOIUrl":"https://doi.org/10.1002/ccd.31261","url":null,"abstract":"<p><strong>Background: </strong>A history of hospitalization for heart failure (HHF) before transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement is associated with the prognosis of patients with severe aortic stenosis (AS). However, the impact of prior HHF on clinical outcomes after contemporary TAVI using new-generation transcatheter heart valves (THVs) has not been thoroughly investigated.</p><p><strong>Methods: </strong>Using data from the aLliAnce for exPloring cLinical prospects of AortiC valvE disease (LAPLACE)-TAVI registry, we investigated 2,752 patients who underwent TAVI with new-generation THVs with a median follow-up of 627 days. The primary outcomes were all-cause mortality and heart failure readmission after TAVI.</p><p><strong>Results: </strong>Patients with a history of HHF (n = 809) showed a higher 30-day mortality than patients without prior HHF (n = 1,943). A Kaplan-Meier analysis revealed that the prior HHF group showed a higher incidence of the primary outcome than the non-prior HHF group (27.4% vs. 16.4%, log-rank p = 0.001). In a Cox regression analysis, prior HHF was significantly associated with the risk of the primary outcome, even after adjusting for covariates (hazard ratio, 1.344; 95% confidence interval, 1.103-1.638; p = 0.003). A subanalysis showed that the prior HHF group with ejection fraction (EF) ≥ 50% had a higher risk of the primary outcome than the non-prior HHF group, whereas the prior HHF group with EF < 50% had the worst outcome.</p><p><strong>Conclusion: </strong>A history of prior HHF is associated with worse outcomes in patients with severe AS, both in those with preserved EF and those with reduced EF, even after TAVI using new-generation devices.</p>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microcatheter tip fracture and acute vessel occlusion rescued with subintimal tracking and re-entry: Move the tip 微导管顶端断裂和急性血管闭塞,经内膜下追踪和再通后获救:移动尖端。
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-10 DOI: 10.1002/ccd.31264
Giangiacomi Francesco MD, Mircoli Luca MD, Tumminello Gabriele MD, Carugo Stefano MD

The development of microcatheters capable of advancing through long, calcified, and tortuous vessels, produced an increase in the success rate of complex percutaneous coronary interventions. However, the aggressive manipulation of these materials may lead to potentially severe and threatening complications. We present a case of Turnpike Spiral (Teleflex) tip fracture, which caused an acute occlusion of the proximal right coronary artery. The coronary artery was tortuous and had two heavily calcified lesions in the proximal segment, uncrossable to both small angioplasty balloons and standard microcatheters. After the incarceration of the tip of the Turnpike Spiral in the calcium, it got fractured during the attempt of removing it from the vessel. This led to ST-segment elevation and patient instability. Due to the impossibility of advancing a second guidewire into the true lumen, we decided to proceed to antegrade dissection and re-entry using the scratch-and-go and subintimal tracking and re-entry technique. We placed a guide-extension and we used a Gaia II (Asahi Intecc) to enter the subintimal space and advance over the fractured tip. The wire was exchanged for a Gladius MG (Asahi Intecc), which re-entered the true lumen at the level of the acute margin of the heart. Intravascular ultrasound was used to confirm the re-entry point, and three drug eluting stents were placed. In this way we rapidly restored the flow in the right coronary artery, and we prevented a myocardial infarction.

能够穿过钙化和迂曲的长血管的微导管的开发提高了复杂经皮冠状动脉介入治疗的成功率。然而,对这些材料的积极操作可能会导致潜在的严重并发症。我们介绍了一例 Turnpike Spiral(Teleflex)尖端断裂导致右冠状动脉近端急性闭塞的病例。该冠状动脉迂曲,近段有两个严重钙化的病变,小血管成形球囊和标准微导管都无法穿过。Turnpike Spiral 的尖端被钙化物卡住后,在试图将其从血管中取出时发生断裂。这导致了 ST 段抬高和患者的不稳定。由于无法将第二根导丝推进到真正的管腔中,我们决定使用 "划痕-走行 "和 "内膜下追踪-再入 "技术进行前行剥离和再入。我们放置了一个导引延长器,并使用 Gaia II(Asahi Intecc)进入内膜下间隙,在断裂的顶端推进。将导线换成 Gladius MG(Asahi Intecc),在心脏急性边缘水平重新进入真腔。利用血管内超声确认了再进入点,并放置了三个药物洗脱支架。通过这种方法,我们迅速恢复了右冠状动脉的血流,避免了心肌梗死的发生。
{"title":"Microcatheter tip fracture and acute vessel occlusion rescued with subintimal tracking and re-entry: Move the tip","authors":"Giangiacomi Francesco MD,&nbsp;Mircoli Luca MD,&nbsp;Tumminello Gabriele MD,&nbsp;Carugo Stefano MD","doi":"10.1002/ccd.31264","DOIUrl":"10.1002/ccd.31264","url":null,"abstract":"<p>The development of microcatheters capable of advancing through long, calcified, and tortuous vessels, produced an increase in the success rate of complex percutaneous coronary interventions. However, the aggressive manipulation of these materials may lead to potentially severe and threatening complications. We present a case of Turnpike Spiral (Teleflex) tip fracture, which caused an acute occlusion of the proximal right coronary artery. The coronary artery was tortuous and had two heavily calcified lesions in the proximal segment, uncrossable to both small angioplasty balloons and standard microcatheters. After the incarceration of the tip of the Turnpike Spiral in the calcium, it got fractured during the attempt of removing it from the vessel. This led to ST-segment elevation and patient instability. Due to the impossibility of advancing a second guidewire into the true lumen, we decided to proceed to antegrade dissection and re-entry using the scratch-and-go and subintimal tracking and re-entry technique. We placed a guide-extension and we used a Gaia II (Asahi Intecc) to enter the subintimal space and advance over the fractured tip. The wire was exchanged for a Gladius MG (Asahi Intecc), which re-entered the true lumen at the level of the acute margin of the heart. Intravascular ultrasound was used to confirm the re-entry point, and three drug eluting stents were placed. In this way we rapidly restored the flow in the right coronary artery, and we prevented a myocardial infarction.</p>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":"104 6","pages":"1220-1224"},"PeriodicalIF":2.1,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes of DCB and DES for the treatment of in-stent restenosis in relation to the vessel size DCB和DES治疗支架内再狭窄的长期疗效与血管大小有关。
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-09 DOI: 10.1002/ccd.31225
Sylwia Iwańczyk MD, PhD, Rafał Wolny MD, Rafał Januszek MD, PhD, Robert J. Gil MD, PhD, Bernardo Cortese MD, Piotr Kubler MD, PhD, Wojciech Wojakowski MD, PhD, Marek Grygier MD, PhD, Maciej Lesiak MD, PhD, Wojciech Wańha MD, PhD

Background

Percutaneous coronary intervention (PCI) with drug-coated balloons (DCB) or drug-eluting stents (DES) are well-established treatments for in-stent restenosis, however little is known about the impact of vessel size on the outcomes. The study aimed to evaluate the efficacy and safety profile of DCB versus DES in DES in-stent restenosis depending on the vessel size.

Methods

Consecutive patients with DES in-stent restenosis who underwent PCI between January 2010 and February 2018 entered the registry with a long-term follow-up. Patients who received DCB at the index procedure were compared with those who received DES in three subgroups depending on the vessel size (≤2.5 mm; 2.5–3.5 mm; >3.5 mm). Data were analyzed using propensity score matching and Kaplan-Meier estimator plots.

Results

Among 1,374 patients with DES in-stent restenosis, 615 were treated with DES and 759 with DCB. After propensity score matching, we analyzed 752 patients in the DES and DCB groups at a long-term follow-up. The risk of DOCE did not differ significantly between the DES and DCB groups, both in the overall population (HR 0.85; 95%CI [0.58; 1.26], log-rank p = 0.41) and when divided into small (HR 0.84; 95%CI [0.36; 1.95], log-rank p = 0.70), medium-sized (HR 0.90; 95%CI [0.49; 1.65], log-rank p = 0.73), and large-sized (HR 0.81; 95%CI [0.42; 1.53], log-rank p = 0.50) coronary arteries. The incidence of all-cause death was significantly higher in the overall DES population (HR 4.03; 95%CI [2.40; 6.79], log-rank p < 0.001) and subgroup of small (HR 5.54; 95%CI [1.80; 17.02], log-rank p = 0.003), medium-sized (HR 4.37; 95%CI [1.92; 9.94], log-rank p = 0.009) and large-sized coronary arteries (HR 3.26; 95%CI [1.35; 7.86], log-rank p = 0.02).

Conclusions

DES and DCB strategies are comparable methods of treating ISR regardless of the diameter of the treated vessel in a long-term follow-up.

背景:使用药物涂层球囊(DCB)或药物洗脱支架(DES)进行经皮冠状动脉介入治疗(PCI)是治疗支架内再狭窄的行之有效的方法,但人们对血管大小对治疗效果的影响知之甚少。该研究旨在评估DCB与DES治疗DES支架内再狭窄的疗效和安全性,具体取决于血管大小:2010年1月至2018年2月期间接受PCI治疗的DES支架内再狭窄连续患者进入登记册,并进行长期随访。根据血管大小(≤2.5 mm;2.5-3.5 mm;>3.5 mm)分为三个亚组,将在指数手术中接受 DCB 的患者与接受 DES 的患者进行比较。采用倾向评分匹配和卡普兰-梅耶估计图分析数据:在1374名DES支架内再狭窄患者中,615人接受了DES治疗,759人接受了DCB治疗。经过倾向评分匹配后,我们对DES组和DCB组的752名患者进行了长期随访分析。无论是在总体人群中(HR 0.85; 95%CI [0.58; 1.26],log-rank p = 0.41),还是在分为小群体时(HR 0.84;95%CI [0.36;1.95],log-rank p = 0.70)、中型(HR 0.90;95%CI [0.49;1.65],log-rank p = 0.73)和大型(HR 0.81;95%CI [0.42;1.53],log-rank p = 0.50)冠状动脉。DES人群的全因死亡发生率明显更高(HR 4.03;95%CI [2.40;6.79],log-rank p 结论:DES和DCB是两种具有可比性的冠状动脉治疗方法:在长期随访中,无论治疗血管的直径如何,DES和DCB都是治疗ISR的可比方法。
{"title":"Long-term outcomes of DCB and DES for the treatment of in-stent restenosis in relation to the vessel size","authors":"Sylwia Iwańczyk MD, PhD,&nbsp;Rafał Wolny MD,&nbsp;Rafał Januszek MD, PhD,&nbsp;Robert J. Gil MD, PhD,&nbsp;Bernardo Cortese MD,&nbsp;Piotr Kubler MD, PhD,&nbsp;Wojciech Wojakowski MD, PhD,&nbsp;Marek Grygier MD, PhD,&nbsp;Maciej Lesiak MD, PhD,&nbsp;Wojciech Wańha MD, PhD","doi":"10.1002/ccd.31225","DOIUrl":"10.1002/ccd.31225","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Percutaneous coronary intervention (PCI) with drug-coated balloons (DCB) or drug-eluting stents (DES) are well-established treatments for in-stent restenosis, however little is known about the impact of vessel size on the outcomes. The study aimed to evaluate the efficacy and safety profile of DCB versus DES in DES in-stent restenosis depending on the vessel size.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Consecutive patients with DES in-stent restenosis who underwent PCI between January 2010 and February 2018 entered the registry with a long-term follow-up. Patients who received DCB at the index procedure were compared with those who received DES in three subgroups depending on the vessel size (≤2.5 mm; 2.5–3.5 mm; &gt;3.5 mm). Data were analyzed using propensity score matching and Kaplan-Meier estimator plots.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 1,374 patients with DES in-stent restenosis, 615 were treated with DES and 759 with DCB. After propensity score matching, we analyzed 752 patients in the DES and DCB groups at a long-term follow-up. The risk of DOCE did not differ significantly between the DES and DCB groups, both in the overall population (HR 0.85; 95%CI [0.58; 1.26], log-rank <i>p</i> = 0.41) and when divided into small (HR 0.84; 95%CI [0.36; 1.95], log-rank <i>p</i> = 0.70), medium-sized (HR 0.90; 95%CI [0.49; 1.65], log-rank <i>p</i> = 0.73), and large-sized (HR 0.81; 95%CI [0.42; 1.53], log-rank <i>p</i> = 0.50) coronary arteries. The incidence of all-cause death was significantly higher in the overall DES population (HR 4.03; 95%CI [2.40; 6.79], log-rank <i>p</i> &lt; 0.001) and subgroup of small (HR 5.54; 95%CI [1.80; 17.02], log-rank <i>p</i> = 0.003), medium-sized (HR 4.37; 95%CI [1.92; 9.94], log-rank <i>p</i> = 0.009) and large-sized coronary arteries (HR 3.26; 95%CI [1.35; 7.86], log-rank <i>p</i> = 0.02).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>DES and DCB strategies are comparable methods of treating ISR regardless of the diameter of the treated vessel in a long-term follow-up.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":"104 6","pages":"1168-1177"},"PeriodicalIF":2.1,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of iatrogenic ascending aortic dissection after percutaneous intervention of chronic total occlusion. 经皮介入治疗慢性全闭塞后的先天性升主动脉夹层管理。
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-09 DOI: 10.1002/ccd.31262
Ahmad Safdar, Laura Young, Jaikirshan Khatri

Background: This study highlights the prevalence and conservative management strategies of iatrogenic ascending aortic dissection after percutaneous intervention (PCI) of chronic total occlusion (CTO).

Methods: Retrospective analysis on patients who underwent CTO PCI from one medical center from 2020 to 2022 was performed by two operators. Data was obtained from the Prospective Global Registry for the Study of CTO database.

Results: Out of 318 patients, there were six reported cases of iatrogenic ascending aortic dissection. The causes of dissection included guiding catheter trauma, antegrade injection, two retrograde injection, and two cases of balloon rupture after lithotripsy. IVUS-guided stenting of the coronary back to the origin to seal the entry of the dissection flap occurred in two patients. All patients had a conservative management approach. No patient had to undergo urgent surgery.

Conclusion: While the incidence remains rare, complications, including aortic dissection, are more frequent in CTO PCI as compared to non-CTO PCI. IVUS can be used to complete coronary intervention so long as the patient remains clinically and hemodynamically stable. Patients should have formal imaging with either transesophageal echocardiogram or computed tomography angiography. The outcomes of patients who experience iatrogenic aortic dissection during CTO PCI with stable coronary disease seem to be better than in patients with acute coronary syndrome.

背景:本研究强调了经皮介入治疗(PCI)后先天性升主动脉夹层的发生率和保守治疗策略:本研究强调了慢性全闭塞(CTO)经皮介入治疗(PCI)后先天性升主动脉夹层的发生率和保守治疗策略:方法:由两名操作者对一家医疗中心在2020年至2022年期间接受CTO PCI的患者进行回顾性分析。数据来自前瞻性全球 CTO 研究注册数据库:在318例患者中,有6例报告了先天性升主动脉夹层。夹层的原因包括导引导管创伤、前向注射、两次逆行注射以及两次碎石后球囊破裂。有两名患者在IVUS引导下对冠状动脉进行了支架植入手术,以堵住夹层瓣的入口。所有患者都采取了保守治疗方法。结论:结论:虽然发生率仍然罕见,但与非 CTO PCI 相比,包括主动脉夹层在内的并发症在 CTO PCI 中更为常见。只要患者临床和血流动力学保持稳定,就可以使用 IVUS 完成冠状动脉介入治疗。患者应接受正规的经食道超声心动图或计算机断层扫描血管造影检查。在冠状动脉疾病稳定的情况下进行 CTO PCI 时发生先天性主动脉夹层的患者的预后似乎优于急性冠状动脉综合征患者。
{"title":"Management of iatrogenic ascending aortic dissection after percutaneous intervention of chronic total occlusion.","authors":"Ahmad Safdar, Laura Young, Jaikirshan Khatri","doi":"10.1002/ccd.31262","DOIUrl":"https://doi.org/10.1002/ccd.31262","url":null,"abstract":"<p><strong>Background: </strong>This study highlights the prevalence and conservative management strategies of iatrogenic ascending aortic dissection after percutaneous intervention (PCI) of chronic total occlusion (CTO).</p><p><strong>Methods: </strong>Retrospective analysis on patients who underwent CTO PCI from one medical center from 2020 to 2022 was performed by two operators. Data was obtained from the Prospective Global Registry for the Study of CTO database.</p><p><strong>Results: </strong>Out of 318 patients, there were six reported cases of iatrogenic ascending aortic dissection. The causes of dissection included guiding catheter trauma, antegrade injection, two retrograde injection, and two cases of balloon rupture after lithotripsy. IVUS-guided stenting of the coronary back to the origin to seal the entry of the dissection flap occurred in two patients. All patients had a conservative management approach. No patient had to undergo urgent surgery.</p><p><strong>Conclusion: </strong>While the incidence remains rare, complications, including aortic dissection, are more frequent in CTO PCI as compared to non-CTO PCI. IVUS can be used to complete coronary intervention so long as the patient remains clinically and hemodynamically stable. Patients should have formal imaging with either transesophageal echocardiogram or computed tomography angiography. The outcomes of patients who experience iatrogenic aortic dissection during CTO PCI with stable coronary disease seem to be better than in patients with acute coronary syndrome.</p>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ProGlide-AngioSeal versus ProGlide-FemoSeal for vascular access hemostasis posttranscatheter aortic valve implantation 用于经导管主动脉瓣植入术后血管通路止血的 ProGlide-AngioSeal 与 ProGlide-FemoSeal 比较。
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-08 DOI: 10.1002/ccd.31259
Mohamed Samy MD, Martin Landt MD, Nader Mankerious MD, Arief Kurniadi MD, Sultan Alotaibi MD, MSc, Ralph Toelg MD, Mohamed Abdel-Wahab MD, Holger Nef MD, Abdelhakim Allali MD, Gert Richardt MD, Karim Elbasha MD

Background

The hybrid strategy combining plug-based and suture-based vascular closure devices (VCD) was introduced as a promising technique for vascular access hemostasis after transcatheter aortic valve implantation (TAVI) with satisfactory outcomes. However, data comparing two plug-based VCDs each in the combination with a suture-based VCD, namely ProGlide/AngioSeal (P/AS) with ProGlide/FemoSeal (P/FS) VCDs, is still lacking.

Aims

To compare the 30-day outcome of the hybrid strategy using P/AS versus P/FS for vascular access site closure after TAVI.

Methods

A retrospective single-center observational study included 608 patients recruited from a prospective TAVI registry between 2016 and 2022. The composite endpoint was defined as any VCD-related major vascular complications and/or bleeding more than type 1 according to Valve Academic Research Consortium criteria.

Results

The current study reported a significantly higher rate of composite endpoint in P/AS group, which was driven by a higher rate of major bleeding (5.4% vs. 1.4%, p = 0.036). We also found a higher rate of VCD-related minor bleeding in P/AS group (16.3% vs. 8.1%, p = 0.013). Successful access site hemostasis was achieved in 71.7% of P/AS group versus 83.1% in P/FS group (p = 0.006). The presence of anterior wall calcification at the access site was significantly associated with the composite endpoint (adj odds ratio 2.49; 95% confidence interval (1.08–5.75), p = 0.032).

Conclusion

The hybrid strategy for large bore vascular access closure using P/FS showed a potentially better 30-day outcomes compared with P/AS. The presence of anterior calcification at the access site carries a significant risk of VCD-related complications.

背景:经导管主动脉瓣植入术(TAVI)后的血管通路止血中,将塞子式和缝线式血管闭合器(VCD)相结合的混合策略是一种很有前景的技术,并取得了令人满意的结果。然而,目前仍缺乏将两种塞式 VCD(即 ProGlide/AngioSeal (P/AS)和 ProGlide/FemoSeal (P/FS) VCD)与缝合式 VCD(即 ProGlide/AngioSeal (P/AS)和 ProGlide/FemoSeal (P/FS)VCD)进行比较的数据:一项回顾性单中心观察研究纳入了2016年至2022年间从前瞻性TAVI登记处招募的608名患者。根据瓣膜学术研究联盟的标准,复合终点定义为任何与 VCD 相关的主要血管并发症和/或出血超过 1 型:目前的研究报告显示,P/AS 组的复合终点发生率明显较高,主要原因是大出血发生率较高(5.4% vs. 1.4%,P = 0.036)。我们还发现,P/AS 组的 VCD 相关轻微出血率更高(16.3% 对 8.1%,p = 0.013)。P/AS组71.7%的患者成功止血,而P/FS组为83.1%(P = 0.006)。入路部位前壁钙化与综合终点显著相关(辅助几率比2.49;95%置信区间(1.08-5.75),p = 0.032):结论:与P/AS相比,采用P/FS混合策略关闭大口径血管通路的30天疗效可能更好。通路部位出现前方钙化会带来 VCD 相关并发症的重大风险。
{"title":"ProGlide-AngioSeal versus ProGlide-FemoSeal for vascular access hemostasis posttranscatheter aortic valve implantation","authors":"Mohamed Samy MD,&nbsp;Martin Landt MD,&nbsp;Nader Mankerious MD,&nbsp;Arief Kurniadi MD,&nbsp;Sultan Alotaibi MD, MSc,&nbsp;Ralph Toelg MD,&nbsp;Mohamed Abdel-Wahab MD,&nbsp;Holger Nef MD,&nbsp;Abdelhakim Allali MD,&nbsp;Gert Richardt MD,&nbsp;Karim Elbasha MD","doi":"10.1002/ccd.31259","DOIUrl":"10.1002/ccd.31259","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The hybrid strategy combining plug-based and suture-based vascular closure devices (VCD) was introduced as a promising technique for vascular access hemostasis after transcatheter aortic valve implantation (TAVI) with satisfactory outcomes. However, data comparing two plug-based VCDs each in the combination with a suture-based VCD, namely ProGlide/AngioSeal (P/AS) with ProGlide/FemoSeal (P/FS) VCDs, is still lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To compare the 30-day outcome of the hybrid strategy using P/AS versus P/FS for vascular access site closure after TAVI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective single-center observational study included 608 patients recruited from a prospective TAVI registry between 2016 and 2022. The composite endpoint was defined as any VCD-related major vascular complications and/or bleeding more than type 1 according to Valve Academic Research Consortium criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The current study reported a significantly higher rate of composite endpoint in P/AS group, which was driven by a higher rate of major bleeding (5.4% vs. 1.4%, <i>p</i> = 0.036). We also found a higher rate of VCD-related minor bleeding in P/AS group (16.3% vs. 8.1%, <i>p</i> = 0.013). Successful access site hemostasis was achieved in 71.7% of P/AS group versus 83.1% in P/FS group (<i>p</i> = 0.006). The presence of anterior wall calcification at the access site was significantly associated with the composite endpoint (adj odds ratio 2.49; 95% confidence interval (1.08–5.75), <i>p</i> = 0.032).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The hybrid strategy for large bore vascular access closure using P/FS showed a potentially better 30-day outcomes compared with P/AS. The presence of anterior calcification at the access site carries a significant risk of VCD-related complications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":"104 6","pages":"1251-1259"},"PeriodicalIF":2.1,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coagulation after transcatheter aortic valve replacement: Still a black box? 经导管主动脉瓣置换术后的凝血问题:仍是黑匣子?
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-07 DOI: 10.1002/ccd.31258
Dr. N. Patrick Mayr MD, FACC, Dr. Yousuke Taniguchi MD
<p>Pioneering roots of transcatheter aortic valve replacement (TAVR) date back to the early 1990s when Andersen and colleagues first presented their prototype of a transcatheter valve. Cribier achieved a clinical breakthrough by implanting a transcatheter aortic valve in a critically ill patient in 2002. Since then, TAVR has become a routine therapy for elderly patients with acquired aortic valve stenosis. For this procedure, sufficient periprocedural anticoagulation is mandatory. The implantation of potentially thrombogenic material into the cardiovascular system harbors the risk of thrombotic events, including stroke or bioprosthetic valve thrombosis, to name just a few.<span><sup>1</sup></span> Despite significant technical advances since the introduction of transfemoral TAVR, vascular bleeding complications still occur.<span><sup>2</sup></span> Finding the right balance between thrombosis and bleeding after the procedure is equally important. Thrombin, antithrombin, fibrinogen, and platelets play a vital role in the coagulation cascade. The course of these factors is essential to understand changes in coagulation after TAVR.</p><p>In the current issue of this journal, Katayama and colleagues have addressed this topic in a prospective single-center observational study.<span><sup>3</sup></span> Almost half of the initial 539 patients were excluded to finally analyze a clean patient cohort, and the most frequent valve types (balloon-expandable and self-expandable) were used. Thrombin-antithrombin complex (TAT) and Fibrin degradation products (FDP) were used as surrogate parameters for changes in the coagulation system.</p><p>TAT is a coagulation marker and is evidence of increased thrombin formation or thrombosis. Conversely, FDP is a marker for fibrinolysis. Finally, the drop of platelets was observed over time.</p><p>Interestingly, a dynamic shift of coagulation status, such as a marked increase of the TAT, was observed in the very early phase after TAVR (first hour). Simultaneously—and with a high correlation to the TAT peak—a significant drop of platelets was seen. It is well known that platelet drop occurs after TAVI<span><sup>4</sup></span>; however, the mechanism is not clearly understood. Especially the higher TAT levels and more significant platelet drop in patients with balloon-expandable transcatheter valves require further investigation. In contrast to the dynamic changes of TAT, FDP levels increased more gradually and consistently in both valve types.</p><p>This study has provided insights into the coagulation system and platelets after TAVR; nevertheless, open questions remain. The authors hypothesize that the drop in platelet count may be due to mechanical destruction, overconsumption, or rapid shear stress. However, other studies have additionally shown a significant drop in hemoglobin levels during and in the early period after the procedure.<span><sup>4</sup></span> However, this drop may also be caused by bleeding or hemodilut
经导管主动脉瓣置换术(TAVR)的先驱可追溯到 20 世纪 90 年代初,当时安德森及其同事首次展示了他们的经导管瓣膜原型。2002 年,Cribier 为一名重症患者植入了经导管主动脉瓣,实现了临床突破。从那时起,经导管主动脉瓣置换术已成为老年主动脉瓣狭窄患者的常规治疗方法。对于这种手术,必须在术前进行充分的抗凝治疗。在心血管系统中植入可能导致血栓形成的材料存在血栓事件的风险,包括中风或生物人工瓣膜血栓形成等。1 尽管自经口 TAVR 推出以来取得了重大的技术进步,但血管出血并发症仍时有发生。凝血酶、抗凝血酶、纤维蛋白原和血小板在凝血级联反应中起着至关重要的作用。在本期杂志中,Katayama 及其同事在一项前瞻性单中心观察研究中探讨了这一主题。3 他们排除了最初 539 例患者中的近一半,最终分析了一个干净的患者队列,并使用了最常见的瓣膜类型(球囊扩张型和自扩张型)。凝血酶-抗凝血酶复合物(TAT)和纤维蛋白降解产物(FDP)被用作凝血系统变化的替代参数。相反,FDP 是纤维蛋白溶解的标志物。有趣的是,在 TAVR 术后的早期阶段(第一小时),凝血状态发生了动态变化,如 TAT 明显升高。与此同时,血小板显著下降,且与 TAT 峰值高度相关。众所周知,TAVI4 术后会出现血小板下降,但其机制尚不清楚。尤其是球囊扩张经导管瓣膜患者的 TAT 水平更高,血小板下降更明显,这需要进一步研究。与 TAT 的动态变化相比,FDP 水平在两种瓣膜类型中的增长更为渐进和一致。这项研究提供了有关 TAVR 术后凝血系统和血小板的见解;然而,仍有一些问题有待解决。作者假设,血小板数量下降可能是由于机械性破坏、过度消耗或快速剪切应力造成的。然而,其他研究也表明,在手术过程中和术后早期,血红蛋白水平会显著下降4 。这种造影剂和输注液在血小板和血红蛋白下降中的作用至今尚未研究清楚。实验研究表明,使用较高剂量的原胺可减少凝血酶的生成。原胺明显减少了人体血浆中组织因子引发的凝血酶的生成。5 目前尚不清楚不同剂量的原胺对 TAVR 患者术后凝血酶生成过程的影响。经导管主动脉瓣置换术后的凝血问题--2024 年仍是一个黑匣子?也许是的,但Katayama及其同事的出色研究为这一黑箱投下了曙光,现在它已变成了深灰色。该领域需要更多的研究。作者声明无利益冲突。
{"title":"Coagulation after transcatheter aortic valve replacement: Still a black box?","authors":"Dr. N. Patrick Mayr MD, FACC,&nbsp;Dr. Yousuke Taniguchi MD","doi":"10.1002/ccd.31258","DOIUrl":"10.1002/ccd.31258","url":null,"abstract":"&lt;p&gt;Pioneering roots of transcatheter aortic valve replacement (TAVR) date back to the early 1990s when Andersen and colleagues first presented their prototype of a transcatheter valve. Cribier achieved a clinical breakthrough by implanting a transcatheter aortic valve in a critically ill patient in 2002. Since then, TAVR has become a routine therapy for elderly patients with acquired aortic valve stenosis. For this procedure, sufficient periprocedural anticoagulation is mandatory. The implantation of potentially thrombogenic material into the cardiovascular system harbors the risk of thrombotic events, including stroke or bioprosthetic valve thrombosis, to name just a few.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Despite significant technical advances since the introduction of transfemoral TAVR, vascular bleeding complications still occur.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Finding the right balance between thrombosis and bleeding after the procedure is equally important. Thrombin, antithrombin, fibrinogen, and platelets play a vital role in the coagulation cascade. The course of these factors is essential to understand changes in coagulation after TAVR.&lt;/p&gt;&lt;p&gt;In the current issue of this journal, Katayama and colleagues have addressed this topic in a prospective single-center observational study.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Almost half of the initial 539 patients were excluded to finally analyze a clean patient cohort, and the most frequent valve types (balloon-expandable and self-expandable) were used. Thrombin-antithrombin complex (TAT) and Fibrin degradation products (FDP) were used as surrogate parameters for changes in the coagulation system.&lt;/p&gt;&lt;p&gt;TAT is a coagulation marker and is evidence of increased thrombin formation or thrombosis. Conversely, FDP is a marker for fibrinolysis. Finally, the drop of platelets was observed over time.&lt;/p&gt;&lt;p&gt;Interestingly, a dynamic shift of coagulation status, such as a marked increase of the TAT, was observed in the very early phase after TAVR (first hour). Simultaneously—and with a high correlation to the TAT peak—a significant drop of platelets was seen. It is well known that platelet drop occurs after TAVI&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;; however, the mechanism is not clearly understood. Especially the higher TAT levels and more significant platelet drop in patients with balloon-expandable transcatheter valves require further investigation. In contrast to the dynamic changes of TAT, FDP levels increased more gradually and consistently in both valve types.&lt;/p&gt;&lt;p&gt;This study has provided insights into the coagulation system and platelets after TAVR; nevertheless, open questions remain. The authors hypothesize that the drop in platelet count may be due to mechanical destruction, overconsumption, or rapid shear stress. However, other studies have additionally shown a significant drop in hemoglobin levels during and in the early period after the procedure.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; However, this drop may also be caused by bleeding or hemodilut","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":"104 6","pages":"1322-1323"},"PeriodicalIF":2.1,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ccd.31258","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety, efficacy, and optical coherence tomography insights into intravascular lithotripsy for the modification of noneruptive calcified nodules. 血管内碎石术治疗非破裂性钙化结节的安全性、疗效和光学相干断层扫描研究。
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-04 DOI: 10.1002/ccd.31260
Okasha Tahir, Syed Ibad Ali, Fatima Zehra, Laiba Shamim, Muhammad Umar
{"title":"Safety, efficacy, and optical coherence tomography insights into intravascular lithotripsy for the modification of noneruptive calcified nodules.","authors":"Okasha Tahir, Syed Ibad Ali, Fatima Zehra, Laiba Shamim, Muhammad Umar","doi":"10.1002/ccd.31260","DOIUrl":"https://doi.org/10.1002/ccd.31260","url":null,"abstract":"","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic total occlusion percutaneous coronary intervention of anomalous coronary arteries: insights from the PROGRESS CTO registry 异常冠状动脉的慢性全闭塞经皮冠状动脉介入治疗:PROGRESS CTO 登记的启示。
IF 2.1 3区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-04 DOI: 10.1002/ccd.31248
Gustavo M. Hirata MD, Athanasios Rempakos MD, A. Walker Boyd MD, Michaella Alexandrou MD, Deniz Mutlu MD, James W. Choi MD, Paul Poommipanit MD, Jaikirshan J. Khatri MD, Laura Young MD, Rhian Davies DO, MS, Sevket Gorgulu MD, Farouc A. Jaffer MD, PhD, Raj Chandwaney MD, Brian Jefferson MD, Basem Elbarouni MD, Lorenzo Azzalini MD, PhD, MSc, Kathleen E. Kearney MD, Khaldoon Alaswad MD, Mir B. Basir DO, Oleg Krestyaninov MD, Dmitrii Khelimskii MD, Nazif Aygul MD, Nidal Abi-Rafeh MD, Ahmed ElGuindy MD, Omer Goktekin MD, Bavana V. Rangan BDS, MPH, Olga C. Mastrodemos BA, Ahmed Al-Ogaili MD, Yader Sandoval MD, M. Nicholas Burke MD, Emmanouil S. Brilakis MD, Jarrod D. Frizzell MD

Background

There is limited information about the frequency and outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in anomalous coronary arteries (ACA).

Methods

We examined the clinical and angiographic characteristics and procedural outcomes of CTO PCI in ACA among 14,173 patients who underwent 14,470 CTO PCIs at 46 US and non-US centers between 2012 and 2023.

Results

Of 14,470 CTO PCIs, 36 (0.24%) were CTO PCIs in an ACA. ACA patients had similar baseline characteristics as those without an ACA. The type of ACA in which the CTO lesion was found were as follows: anomalous origin of the right coronary artery (ARCA) (17, 48.5%), anomalous origin of left circumflex coronary artery (9, 25.7%), left anterior descending artery and left circumflex artery with separate origins (4, 11.4%), anomalous origin of the left anterior descending artery (2, 5.7%), dual left anterior descending artery (2, 5.7%) and woven coronary artery 1 (2.8%). The Japan CTO score was similar between both groups (2.17 ± 1.32 vs 2.38 ± 1.26, p = 0.30). The target CTO in ACA patients was more likely to have moderate/severe tortuosity (44% vs 28%, p = 0.035), required more often use of retrograde approach (27% vs 12%, p = 0.028), and was associated with longer procedure (142.5 min vs 112.00 min [74.0, 164.0], p = 0.028) and fluoroscopy (56 min [40, 79 ml] vs 42 min [25, 67], p = 0.014) time and higher contrast volume (260 ml [190, 450] vs 200 ml [150, 300], p = 0.004) but had similar procedural (91.4% vs 85.6%, p = 0.46) and technical (91.4% vs 87.0%, p = 0.59) success. No major adverse cardiac events (MACE) were seen in ACA patients (0% [0] vs 1.9% [281] in non-ACA patients, p = 1.00). Two coronary perforations were reported in ACA CTO PCI (p = 0.7 vs. non-ACA CTO PCI).

Conclusions

CTO PCI of ACA comprise 0.24% of all CTO PCIs performed in the PROGRESS CTO registry and was associated with higher procedural complexity but similar technical and procedural success rates and similar MACE compared with non-ACA CTO PCI.

背景:有关异常冠状动脉(ACA)慢性全闭塞(CTO)经皮冠状动脉介入治疗(PCI)的频率和结果的信息有限:有关异常冠状动脉(ACA)慢性全闭塞(CTO)经皮冠状动脉介入治疗(PCI)的频率和结果的信息非常有限:我们研究了2012年至2023年期间在46个美国和非美国中心接受14,173例CTO PCI的14,470名患者的临床和血管造影特征以及ACA CTO PCI的手术结果:在 14,470 例 CTO PCI 中,有 36 例(0.24%)是在 ACA 中进行的 CTO PCI。ACA患者的基线特征与非ACA患者相似。发现 CTO 病变的 ACA 类型如下:右冠状动脉异常起源 (ARCA)(17 例,占 48.5%)、左侧环状冠状动脉异常起源(9 例,占 25.7%)、左前降支动脉和左侧冠状动脉起源不同(4,11.4%)、左前降支动脉起源异常(2,5.7%)、双左前降支动脉(2,5.7%)和编织冠状动脉 1(2.8%)。两组患者的日本 CTO 评分相似(2.17 ± 1.32 vs 2.38 ± 1.26,P = 0.30)。ACA患者的目标CTO更可能有中度/重度迂曲(44% vs 28%,P = 0.035),更经常需要使用逆行入路(27% vs 12%,P = 0.028),手术时间更长(142.5 min vs 112.00 min [74.0, 164.0],P = 0.028)和透视(56 分钟 [40, 79 毫升] vs 42 分钟 [25, 67],p = 0.014)时间,以及更高的造影剂用量(260 毫升 [190, 450] vs 200 毫升 [150, 300],p = 0.004),但手术成功率(91.4% vs 85.6%,p = 0.46)和技术成功率(91.4% vs 87.0%,p = 0.59)相似。ACA患者未发生重大心脏不良事件(MACE)(0% [0] vs 1.9% [281] 非ACA患者,p = 1.00)。ACA CTO PCI中报告了两例冠状动脉穿孔(与非ACA CTO PCI相比,p = 0.7):在 PROGRESS CTO 注册中心进行的所有 CTO PCI 中,ACA CTO PCI 占 0.24%,与非 ACA CTO PCI 相比,ACA CTO PCI 的手术复杂性更高,但技术和手术成功率相似,MACE 相似。
{"title":"Chronic total occlusion percutaneous coronary intervention of anomalous coronary arteries: insights from the PROGRESS CTO registry","authors":"Gustavo M. Hirata MD,&nbsp;Athanasios Rempakos MD,&nbsp;A. Walker Boyd MD,&nbsp;Michaella Alexandrou MD,&nbsp;Deniz Mutlu MD,&nbsp;James W. Choi MD,&nbsp;Paul Poommipanit MD,&nbsp;Jaikirshan J. Khatri MD,&nbsp;Laura Young MD,&nbsp;Rhian Davies DO, MS,&nbsp;Sevket Gorgulu MD,&nbsp;Farouc A. Jaffer MD, PhD,&nbsp;Raj Chandwaney MD,&nbsp;Brian Jefferson MD,&nbsp;Basem Elbarouni MD,&nbsp;Lorenzo Azzalini MD, PhD, MSc,&nbsp;Kathleen E. Kearney MD,&nbsp;Khaldoon Alaswad MD,&nbsp;Mir B. Basir DO,&nbsp;Oleg Krestyaninov MD,&nbsp;Dmitrii Khelimskii MD,&nbsp;Nazif Aygul MD,&nbsp;Nidal Abi-Rafeh MD,&nbsp;Ahmed ElGuindy MD,&nbsp;Omer Goktekin MD,&nbsp;Bavana V. Rangan BDS, MPH,&nbsp;Olga C. Mastrodemos BA,&nbsp;Ahmed Al-Ogaili MD,&nbsp;Yader Sandoval MD,&nbsp;M. Nicholas Burke MD,&nbsp;Emmanouil S. Brilakis MD,&nbsp;Jarrod D. Frizzell MD","doi":"10.1002/ccd.31248","DOIUrl":"10.1002/ccd.31248","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There is limited information about the frequency and outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in anomalous coronary arteries (ACA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We examined the clinical and angiographic characteristics and procedural outcomes of CTO PCI in ACA among 14,173 patients who underwent 14,470 CTO PCIs at 46 US and non-US centers between 2012 and 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 14,470 CTO PCIs, 36 (0.24%) were CTO PCIs in an ACA. ACA patients had similar baseline characteristics as those without an ACA. The type of ACA in which the CTO lesion was found were as follows: anomalous origin of the right coronary artery (ARCA) (17, 48.5%), anomalous origin of left circumflex coronary artery (9, 25.7%), left anterior descending artery and left circumflex artery with separate origins (4, 11.4%), anomalous origin of the left anterior descending artery (2, 5.7%), dual left anterior descending artery (2, 5.7%) and woven coronary artery 1 (2.8%). The Japan CTO score was similar between both groups (2.17 ± 1.32 vs 2.38 ± 1.26, <i>p</i> = 0.30). The target CTO in ACA patients was more likely to have moderate/severe tortuosity (44% vs 28%, <i>p</i> = 0.035), required more often use of retrograde approach (27% vs 12%, <i>p</i> = 0.028), and was associated with longer procedure (142.5 min vs 112.00 min [74.0, 164.0], <i>p</i> = 0.028) and fluoroscopy (56 min [40, 79 ml] vs 42 min [25, 67], <i>p</i> = 0.014) time and higher contrast volume (260 ml [190, 450] vs 200 ml [150, 300], <i>p</i> = 0.004) but had similar procedural (91.4% vs 85.6%, <i>p</i> = 0.46) and technical (91.4% vs 87.0%, <i>p</i> = 0.59) success. No major adverse cardiac events (MACE) were seen in ACA patients (0% [0] vs 1.9% [281] in non-ACA patients, <i>p</i> = 1.00). Two coronary perforations were reported in ACA CTO PCI (<i>p</i> = 0.7 vs. non-ACA CTO PCI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CTO PCI of ACA comprise 0.24% of all CTO PCIs performed in the PROGRESS CTO registry and was associated with higher procedural complexity but similar technical and procedural success rates and similar MACE compared with non-ACA CTO PCI.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":"104 6","pages":"1148-1158"},"PeriodicalIF":2.1,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Catheterization and Cardiovascular Interventions
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1